U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Duloxetine (marketed as Cymbalta) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Duloxetine (marketed as Cymbalta) Information

Duloxetine (marketed as Cymbalta) is included in the class of drugs called selective serotonin/norepinephrine reuptake inhibitors (SNRIs). This class of drugs is used to treat depression, anxiety, and other mood disorders.   

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program, using the contact information at the bottom of this page.

Labeling and Regulatory History from Drugs@FDA

Back to Top